Ariadne Wealth Management’s Alnylam Pharmaceuticals ALNY Stock Holding History

Ariadne Wealth Management’s Portfolio ALNY Stock Details ALNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-677	Closed	-$209K	–	249
2025 Q4	$209K	Sell	677 -26	-4%	-$11.5K	0.09%	240
2025 Q3	$319K	Buy	703 +197	+39%	+$80.2K	0.14%	156
2025 Q2	$219K	Buy	+506	New	+$140K	0.1%	189
2025 Q1	–	Sell	-1,042	Closed	-$286K	–	209
2024 Q4	$286K	Buy	1,042 +187	+22%	+$49.2K	0.13%	155
2024 Q3	$233K	Buy	+855	New	+$223K	0.13%	170

Other funds holding ALNY

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Ariadne Wealth Management's ALNY Position: Q1 2026 in Review

Ariadne Wealth Management sold out of Alnylam Pharmaceuticals (ALNY) in Q1 2026, closing a stake of 677 shares — an estimated $209K sold.

Ariadne Wealth Management first reported a position in ALNY in Q3 2024 and held it in 5 quarters. The position peaked at $319K in Q3 2025. 793 funds tracked by Wall St. Rank hold ALNY as of Q1 2026.

Ariadne Wealth Management reported no remaining Alnylam Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
Ariadne Wealth Management sold 677 Alnylam Pharmaceuticals shares in Q1 2026, an estimated $209K.
Ariadne Wealth Management first reported a position in Alnylam Pharmaceuticals in Q3 2024 and held it in 5 quarters.
Ariadne Wealth Management's Alnylam Pharmaceuticals position peaked at $319K in Q3 2025.
793 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q1 2026.

Based on Ariadne Wealth Management's 13F filing for Q1 2026, filed 18 May 2026.